Microencapsulated solution for gradual release of bromelain

Bromelami Retard® is a microencapsulated bromelain obtained by a patented technology¹ from which spheres with a particle size of 250 μm to 790 μm are obtained.
The starting point for production is an inert core, which is coated with several layers of bromelain. Subsequently, the whole is coated with polymeric membranes that confer gastroresistance to the microcapsules.

This ensures that all the active ingredient, namely bromelain, can reach the intestine, the organ responsible for its absorption. The microcapsule is composed of sucrose, corn starch, talc, shellac, hydroxypropylcellulose and ethyl alcohol.

¹MINIACTIVES® Technology, Registered trademark by IPS srl

Reason why

Bromelami Retard® is able to reach the intestine releasing bromelain gradually over time and allowing its absorption.

The gastroresistance of Bromelami Retard® has been demonstrated by in vitro studies with simulated gastric and intestinal fluids. Microencapsulation is able to make the product resistant to the acid pH of the stomach, as there is no increase in proteolytic activity (measured in GDU/g) in the solution used for the test during the two-hour test, while in the intestine slow release of bromelain has been demonstrated up to 48 hours after microcapsule breakage.

There is a higher and prolonged release of bromelain into the intestinal fluid over time (up to 48 hours), with slow kinetics compatible with intestinal transit times compared to gastric ones. Photomicrographic observations show an unaltered state of its structure when in contact with gastric fluid.


Cardiovascular system: prevention of thrombosis, embolism and cholesterol plaques, control of diabetes and hypertension symptoms, cardioprotective activity.

Articulations: alternative to anti-inflammatory treatments thanks to its analgesic properties.

Immunological system: treatment of chronic inflammation, autoimmune diseases, modulation of T lymphocytes and macrophages.

Gastrointestinal system: anti-adherent effect of pathogenic bacteria on the intestinal mucosa.

Interested in Amilook?

Contact us